Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
Authors
Matthew Stephen Block (ORCID: https://orcid.org/0000-0001-5692-4219)
Samir S. Khariwala (ORCID: https://orcid.org/0000-0002-5579-4990)
Robert R. McWilliams (ORCID: https://orcid.org/0000-0002-8199-5040)
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
Matthew Stephen Block, Samir S. Khariwala, Robert R. McWilliams, Carrie Strand et al.
Citations
6 citations
Journal
Journal for ImmunoTherapy of Cancer
Topics
Cancer Immunotherapy and Biomarkers
Field-Weighted Citation Impact (FWCI)
6.27
article
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
Matthew Stephen Block, Samir S. Khariwala, Robert R. McWilliams, Carrie Strand, Thomas J. Flotte, Heather N. Montane, Garth D. Nelson, Haidong Dong, David Zahrieh, Tina J. Hieken, Courtney L. Erskine, Lisa A. Kottschade, Stephen Johnson, Evidio Domingo‐Musibay, Mara A. Piltin, Anastasios Dimou, Eric P. Grewal, Svetomir N. Markovic, Daniel L. Price, Lu Yang, Jane Yuet Ching Hui, Jun Chen
article en
6 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal for ImmunoTherapy of CancerVol. 13(4)
Institutions
University of Minnesota (US), Mayo Clinic (US), Twin Cities Orthopedics (US), Mayo Clinic in Arizona (US), Mayo Clinic in Florida (US)